Efficacy and tolerability of once-weekly rosuvastatin in patients with previous statin intolerance

Kennedy, Steven P.; Barnas, Gary P.; Schmidt, Michael; Glisczinski, Marcy S.; Paniagua, Angela

doi:10.1016/j.jacl.2011.03.454

Cited by 45 publications

(25 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this double-blind, placebo-controlled crossover study, the mean percentage LDL-C change was 12.2% and 0.4% (p=0.002) for rosuvastatin 5 mg (with uptitration to 10 mg) compared to placebo; myalgias requiring statin cessation were experienced in 20% and 12% of patients, respectively (38). Intermittent dosing strategies have been shown to effectively improve LDL-C, albeit less than daily dosing.…”

Section: Rosuvastatin Shares a Similar Half-life To Atorvastatin (19 mentioning

confidence: 94%

“…Randomized trials assessing daily, every other day, and once weekly dosing have generally shown good statin tolerance and significant LDL-C lowering (38,48). In an 8-week trial evaluating the effect of rosuvastatin 10 mg daily compared to every other day, LDL-C Downloaded by [Imperial College London Library] at 17:48 04 June 2016 was reduced by 48% and 39%, respectively (p=0.001) (48).…”

Section: Rosuvastatin Shares a Similar Half-life To Atorvastatin (19 mentioning

confidence: 99%

“…Other studies have found that once-weekly rosuvastatin is effective and well tolerated among patients not at LDL-C goal and previously unable to tolerate statins because of a history of myalgias (38). In this double-blind, placebo-controlled crossover study, the mean percentage LDL-C change was 12.2% and 0.4% (p=0.002) for rosuvastatin 5 mg (with uptitration to 10 mg) compared to placebo; myalgias requiring statin cessation were experienced in 20% and 12% of patients, respectively (38).…”

Section: Rosuvastatin Shares a Similar Half-life To Atorvastatin (19 mentioning

confidence: 99%

See 2 more Smart Citations

Expert opinion: the therapeutic challenges faced by statin intolerance

Patel

Martin²,

Banach

2016

Expert Opinion on Pharmacotherapy

View full text Add to dashboard Cite

When initiating statin therapy, attention to risk factors for statin intolerance is strongly recommended. Most patients will tolerate some degree of statin therapy; thus statin re-challenge is advisable. If alternative dosing regimens are not tolerated, non-statin medications are acceptable alternatives. To limit errors in the diagnosis of statin intolerance, improvements in clinician-patient communication about the side effects and benefits of statins should be attempted.

show abstract

Section: Rosuvastatin Shares a Similar Half-life To Atorvastatin (19 mentioning

confidence: 94%

Section: Rosuvastatin Shares a Similar Half-life To Atorvastatin (19 mentioning

confidence: 99%

Section: Rosuvastatin Shares a Similar Half-life To Atorvastatin (19 mentioning

confidence: 99%

See 1 more Smart Citation

Expert opinion: the therapeutic challenges faced by statin intolerance

Patel

Martin²,

Banach

2016

Expert Opinion on Pharmacotherapy

View full text Add to dashboard Cite

show abstract

“…In this context, some patients who previously have had statin-induced myalgias may be able to tolerate low doses of statins to achieve some LDL-lowering benefit [18].…”

Section: Currently Available Lipid-lowering Approaches Beyond Statinsmentioning

confidence: 99%

Treatment of Familial Hypercholesterolemia: Is There a Need Beyond Statin Therapy?

Raper

Kolansky

Cuchel

2011

Curr Atheroscler Rep

View full text Add to dashboard Cite

Familial hypercholesterolemia (FH) is a genetic lipid disorder that is characterized by severely elevated cholesterol levels and premature cardiovascular disease. Both the heterozygous and homozygous forms of FH require aggressive cholesterol-lowering therapy. Statins alone frequently do not lower these patients' cholesterol to therapeutic levels, and some patients are intolerant to statins. Combination or monotherapy with other current pharmacotherapies are options, but even with these some FH patients do not meet their low-density lipoprotein (LDL) cholesterol goals. In the cases of statin intolerance, LDL apheresis may be another treatment option. There are currently several novel therapies in development for LDL lowering that target either production or catabolism of LDL, plaque regression, and potentially gene transfer. We conclude that there is a need beyond statins for patients with FH, especially in cases of statin intolerance, and when even the highest doses of statin do not get patients to goal cholesterol levels.

show abstract

“…Previous studies have demonstrated that nondaily statin dosing, ranging from 1 to 4 times a week, can increase tolerability while improving plasma lipid profiles in patients with statin intolerance. [4][5][6][7][8][9][10][11][12] Daily rosuvastatin has been shown to reduce LDL-C by 46%-55%. 13,14 This high efficacy, along with its high potency and long half-life (18-20 hours), 15 makes rosuvastatin in particular an ideal choice for nondaily dosing regimens.…”

mentioning

confidence: 99%